J Korean Med Sci.  2023 Aug;38(34):e263. 10.3346/jkms.2023.38.e263.

Clinical Effectiveness of TetracyclineClass Agents Based Regimens in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Single-Center Retrospective Cohort Study

• Kim SH
• Wi YM
• Peck KR

• KMID: 2545541
• DOI: http://doi.org/10.3346/jkms.2023.38.e263

Abstract

This study evaluated the clinical outcome of carbapenem-resistant Acinetobacter baumannii (CRAB) bacteremia and the clinical effectiveness of tetracyclines-based therapy. In a retrospective cohort study over 5 years period, 108 patients were included in the study. The overall 30-day mortality rate was 71.4%. Pitt’s bacteremia score (PBS) (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.22–1.42 per 1-point), colistin-single regimens (aHR, 0.34; 95% CI, 0.17–0.69), and tetracyclines single/tetracyclines-colistin combination regimens (aHR, 0.18; 95% CI, 0.07–0.48) were independently associated with 30-day mortality. Among patients with a PBS < 6, only tetracycline-containing regimens were associated with decreased mortality. Among patients receiving appropriate definite antimicrobials, the tetracyclines-colistin combination (7 of 7, 100%) tended to a higher 30-day survival rate compared to a tetracycline (7 of 12, 57.1%) or colistin single regimen (10 of 22, 41.6%, P = 0.073). Our findings suggest tetracyclines might be effective for treating CRAB infections when combined with colistin.

Keyword

Carbapenem-Resistance; Extensively Drug Resistant; Acinetobacter baumannii; Tetracyclines; Minocycline; Tigecycline

Figure

• 

  Fig. 1 The overall 30-day survival rate of each regimen.TC = tetracyclines.

Reference

1. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019; 25(8):951–957. PMID: 30914347.

2. Kim D, Lee H, Choi JS, Croney CM, Park KS, Park HJ, et al. The changes in epidemiology of imipenem-resistant Acinetobacter baumannii bacteremia in a pediatric intensive care unit for 17 years. J Korean Med Sci. 2022; 37(24):e196. PMID: 35726147.

3. Lee H, Yoon EJ, Kim D, Jeong SH, Won EJ, Shin JH, et al. Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Euro Surveill. 2018; 23(42):1800047. PMID: 30352640.

4. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of Ampc β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022; 74(12):2089–2114. PMID: 34864936.

5. Shi H, Lee JS, Park SY, Ko Y, Eom JS. Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist. 2019; 12:3925–3934. PMID: 31920347.

6. Seok H, Choi WS, Lee S, Moon C, Park DW, Song JY, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea. J Glob Antimicrob Resist. 2021; 24:429–439. PMID: 33571708.

7. Amat T, Gutiérrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Pérez-Nadales E, Torre-Giménez Á, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018; 24(6):630–634. PMID: 28970161.

8. Yang YS, Lee Y, Tseng KC, Huang WC, Chuang MF, Kuo SC, et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016; 60(7):4047–4054. PMID: 27114274.

9. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018; 18(4):391–400. PMID: 29456043.

10. Saelim W, Changpradub D, Thunyaharn S, Juntanawiwat P, Nulsopapon P, Santimaleeworagun W. Colistin plus sulbactam or fosfomycin against carbapenem-resistant Acinetobacter baumannii: improved efficacy or decreased risk of nephrotoxicity? Infect Chemother. 2021; 53(1):128–140. PMID: 34409786.

11. Kim YA, Park YS. Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea. Korean J Intern Med. 2018; 33(2):247–255. PMID: 29506343.

12. Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J. 2012; 53(5):974–984. PMID: 22869481.

13. Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review. Infect Dis Ther. 2017; 6(2):199–211. PMID: 28357705.

14. Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012; 40(4):332–336. PMID: 22831842.

15. Sung H, Choi SJ, Yoo S, Kim MN. In vitro antimicrobial synergy against imipenem-resistant Acinetobacter baumannii. Korean J Lab Med. 2007; 27(2):111–117. PMID: 18094561.